Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 20, 2023

SELL
$65.71 - $74.53 $12,484 - $14,160
-190 Reduced 5.02%
3,593 $249,000
Q4 2022

Jan 24, 2023

SELL
$68.48 - $81.09 $234,270 - $277,408
-3,421 Reduced 47.49%
3,783 $0
Q3 2022

Oct 13, 2022

SELL
$0.13 - $76.84 $34,531 - $20.4 Million
-265,628 Reduced 97.36%
7,204 $512,000
Q2 2022

Aug 11, 2022

SELL
$72.62 - $79.98 $595,629 - $655,995
-8,202 Reduced 2.92%
272,832 $21 Million
Q1 2022

Apr 26, 2022

BUY
$61.48 - $73.72 $8,914 - $10,689
145 Added 0.05%
281,034 $20.5 Million
Q4 2021

Jan 26, 2022

BUY
$53.63 - $62.52 $137,614 - $160,426
2,566 Added 0.92%
280,889 $17.5 Million
Q3 2021

Oct 26, 2021

BUY
$59.17 - $69.31 $328,689 - $385,017
5,555 Added 2.04%
278,323 $16.5 Million
Q2 2021

Jul 20, 2021

BUY
$61.91 - $67.42 $284,228 - $309,525
4,591 Added 1.71%
272,768 $18.2 Million
Q1 2021

Apr 30, 2021

BUY
$59.34 - $66.74 $1.87 Million - $2.11 Million
31,585 Added 13.35%
268,177 $16.9 Million
Q4 2020

Jan 27, 2021

BUY
$57.74 - $65.43 $427,564 - $484,509
7,405 Added 3.23%
236,592 $14.7 Million
Q3 2020

Oct 26, 2020

BUY
$57.43 - $63.64 $347,049 - $384,576
6,043 Added 2.71%
229,187 $13.8 Million
Q2 2020

Jul 23, 2020

BUY
$54.82 - $64.09 $193,185 - $225,853
3,524 Added 1.6%
223,144 $13.1 Million
Q1 2020

Apr 16, 2020

BUY
$46.4 - $67.43 $1.68 Million - $2.44 Million
36,208 Added 19.74%
219,620 $12.2 Million
Q4 2019

Jan 22, 2020

BUY
$49.21 - $64.19 $238,865 - $311,578
4,854 Added 2.72%
183,412 $11.8 Million
Q3 2019

Oct 24, 2019

BUY
$42.77 - $50.71 $7.64 Million - $9.05 Million
178,558 New
178,558 $9.06 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $126B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Norris Perne & French LLP Portfolio

Follow Norris Perne & French LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norris Perne & French LLP, based on Form 13F filings with the SEC.

News

Stay updated on Norris Perne & French LLP with notifications on news.